1. Home
  2. ADSE vs ESPR Comparison

ADSE vs ESPR Comparison

Compare ADSE & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADS-TEC ENERGY PLC

ADSE

ADS-TEC ENERGY PLC

HOLD

Current Price

$11.40

Market Cap

858.0M

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.16

Market Cap

814.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADSE
ESPR
Founded
1980
2008
Country
Ireland
United States
Employees
302
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
858.0M
814.3M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
ADSE
ESPR
Price
$11.40
$3.16
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.75
AVG Volume (30 Days)
2.5K
8.7M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
$549.86
N/A
Revenue Next Year
N/A
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$7.89
$0.95
52 Week High
$13.90
$4.18

Technical Indicators

Market Signals
Indicator
ADSE
ESPR
Relative Strength Index (RSI) 48.85 70.72
Support Level $11.20 $3.11
Resistance Level $12.01 $3.18
Average True Range (ATR) 0.40 0.01
MACD 0.00 -0.02
Stochastic Oscillator 62.28 77.78

Price Performance

Historical Comparison
ADSE
ESPR

About ADSE ADS-TEC ENERGY PLC

ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: